echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > China's hepatitis C war heats up: Johnson & Johnson's new hepatitis C drug is approved, and MSD submits its listing application

    China's hepatitis C war heats up: Johnson & Johnson's new hepatitis C drug is approved, and MSD submits its listing application

    • Last Update: 2017-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Medical magic cube data: on August 28, 2017, in addition to the big news of Gilead's merger and acquisition of kite, it was also a very uneasy day for China's hepatitis C drug market The approval status of simeprevir's listing application for jxhs160064 has changed to "certificate preparation completed - approved document" Although the drug approval number has not been released yet, according to the person familiar with the matter, simeprevir has been approved by CFDA for listing Johnson & Johnson is also the second pharmaceutical company to list new hepatitis C drugs in China after BMS In addition, the listing application submitted by zepatier, a new drug for hepatitis C, was accepted by CDE on the same day However, during the whole registration process of zepatier, its common name is quite variable The first clinical application for new hepatitis C drugs (jxhl14002232014 / 7 / 16) was submitted in China under the code of mk-5172a, and then the clinical application was submitted under the common name of elbasvir / grazoprevir tablets (jxhl1600103216 / 9 / 12) and ebashweg zopuvir tablets (jxhl17000012017 / 1 / 22) respectively At the time of submitting the application for listing, the generic name became the elbawegrarevir film You should have known more about the current situation of hepatitis C drug market The fierce price competition and emerging new products made several giants who were still in the limelight a year ago unhappy in the first half of this year The sales of sovaldi, harvoni and viekira fell sharply in 2017h1 compared with the same period in 2016 Although zepatier achieved $895 million in the first half of the year, the price advantage of the new all gene hepatitis C drug maviret with a course of treatment of $26400 (8 weeks) just launched by abbvie is almost nonexistent There is also a lot of pressure to maintain such performance in the second half of the year In the eyes of giants, China, the big market of hepatitis C, is basically the only one left in the world But competition in the Chinese hepatitis C market is also fierce Several domestic and foreign enterprises' applications for the listing of oral hepatitis C drugs have been included in the priority review by CDE, and BMS cooperated with Shanghai Pharmaceutical and insurance institutions to carry out market promotion work such as "pay as you go" innovative insurance project as soon as the "ashureway" + "dalatawei" portfolio was approved for listing on June 21 this year The listing of Johnson simmerevir, a new oral hepatitis C drug submitted for listing in China, will undoubtedly heat up the competition in China's hepatitis C drug market Moreover, suofibuvir, danorevir and other varieties will also be listed soon At that time, the scene of foreign price competition may be repeated in China.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.